Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 15;15(7):1959.
doi: 10.3390/pharmaceutics15071959.

Biomaterial Drug Delivery Systems for Prominent Ocular Diseases

Affiliations
Review

Biomaterial Drug Delivery Systems for Prominent Ocular Diseases

Avin Sapowadia et al. Pharmaceutics. .

Abstract

Ocular diseases, such as age-related macular degeneration (AMD) and glaucoma, have had a profound impact on millions of patients. In the past couple of decades, these diseases have been treated using conventional techniques but have also presented certain challenges and limitations that affect patient experience and outcomes. To address this, biomaterials have been used for ocular drug delivery, and a wide range of systems have been developed. This review will discuss some of the major classes and examples of biomaterials used for the treatment of prominent ocular diseases, including ocular implants (biodegradable and non-biodegradable), nanocarriers (hydrogels, liposomes, nanomicelles, DNA-inspired nanoparticles, and dendrimers), microneedles, and drug-loaded contact lenses. We will also discuss the advantages of these biomaterials over conventional approaches with support from the results of clinical trials that demonstrate their efficacy.

Keywords: DNA-inspired janus base nanopieces; biomaterials; hydrogels; nanoparticles; ocular drug delivery; ocular implants.

PubMed Disclaimer

Conflict of interest statement

Yupeng Chen is a co-founder of Eascra Biotech, Inc. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.

Figures

Figure 1
Figure 1
Schematic representation of different sections of the human eye (A), conventional drug delivery techniques (B), and novel drug delivery techniques (C).
Figure 2
Figure 2
Different nanocarriers for ocular drug delivery. Reproduced from Weng et al. [110] under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Figure 3
Figure 3
Self-assembly of nanomicelles and drug encapsulation. Reproduced from Vaishya et al. [128] with permission.
Figure 4
Figure 4
Structure and assembly of (A) JBNTs and (B) nanopieces with RNA as nano-rod delivery vehicles. Reproduced from Sands et al. [149] with permission.
Figure 5
Figure 5
Illustration of a generation 4 (G4) dendrimer with 64 amino groups at the periphery. Image reproduced from Abbasi et al. [154] under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Figure 6
Figure 6
Three main types of microneedle patches for ocular drug delivery. Reproduced from Gupta et al. [160] with permission.
Figure 7
Figure 7
Digital photograph of a dissolvable polymeric microneedle patch supported by a convex polymer (a), stereomicroscopic image with a scale bar of 1 mm (b), and a magnified stereomicroscopic image with scale bar of 200 µm (c). Figure 7 was reproduced from Roy et al. [164] with permission.
Figure 8
Figure 8
Placement of a drug-loaded contact lens on the cornea for ocular drug delivery. Image reproduced from Franco et al. [166] under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

Similar articles

Cited by

References

    1. Hyman L. Epidemiology of Eye Disease in the Elderly. Pt 2Eye. 1987;1:330–341. doi: 10.1038/eye.1987.53. - DOI - PubMed
    1. Zhang X., Beckles G.L., Chou C.-F., Saaddine J.B., Wilson M.R., Lee P.P., Parvathy N., Ryskulova A., Geiss L.S. Socioeconomic Disparity in Use of Eye Care Services among US Adults with Age-Related Eye Diseases: National Health Interview Survey, 2002 and 2008. JAMA Ophthalmol. 2013;131:1198–1206. doi: 10.1001/jamaophthalmol.2013.4694. - DOI - PubMed
    1. Assi L., Chamseddine F., Ibrahim P., Sabbagh H., Rosman L., Congdon N., Evans J., Ramke J., Kuper H., Burton M.J., et al. A Global Assessment of Eye Health and Quality of Life: A Systematic Review of Systematic Reviews. JAMA Ophthalmol. 2021;139:526–541. doi: 10.1001/jamaophthalmol.2021.0146. - DOI - PMC - PubMed
    1. Lee P.P., Feldman Z.W., Ostermann J., Brown D.S., Sloan F.A. Longitudinal Prevalence of Major Eye Diseases. Arch. Ophthalmol. 2003;121:1303–1310. doi: 10.1001/archopht.121.9.1303. - DOI - PubMed
    1. Pascolini D., Mariotti S.P. Global Estimates of Visual Impairment: 2010. Br. J. Ophthalmol. 2012;96:614–618. doi: 10.1136/bjophthalmol-2011-300539. - DOI - PubMed

LinkOut - more resources